Recent developments include continued growth in the installed base of OGM instruments, modest changes in flowcell sales, and ongoing efforts to secure inventory through deposits with contract manufacturers. The company is monitoring geopolitical and macroeconomic risks and the impact of the U.S. government shutdown on its operations.

• The installed base of OGM instruments grew to 387 units as of December 31, 2025, a 4.3% increase from 371 units at the end of 2024 [S1].
• Flowcell sales were 30,171 units in 2025, a slight decrease of 0.4% compared to 2024 [S1].
• Total revenue decreased 7% to $28.5 million in 2025, driven primarily by a decline in service and other revenue [S1].
• The company made weekly deposits totaling approximately $1.9 million in 2025 to its instrument contract manufacturer to secure inventory and raw materials [S1][S2].
• Bionano is monitoring the potential impact of the U.S. government shutdown on manufacturing partners and customers reliant on government funding [S2].
• The company continues to focus on driving utilization and adoption of OGM from its existing installed base, with less emphasis on new instrument placements [S1][S2].
• Net loss improved to $26.4 million in 2025 from $112.0 million in 2024, reflecting cost reductions and restructuring [S1].
• HC Wainwright & Co. maintained a buy recommendation for Bionano Genomics in November 2025 [N3].
• Recent earnings call transcripts provide insights into operational performance and strategic focus [N1][N4].

Bionano Genomics has demonstrated growth in its installed base of OGM instruments and increased consumable sales, indicating adoption of its technology. The integration of OGM data with next-generation sequencing and microarray data via its VIA software offers a comprehensive solution for genomic analysis, potentially streamlining workflows for customers. The company’s reagent rental program supports recurring revenue streams. Recent reductions in operating expenses and restructuring efforts have improved financial performance, reducing net losses significantly compared to prior periods. Continued commercialization efforts and expansion of diagnostic services through Bionano Laboratories may enhance market penetration and revenue diversification.

Bionano Genomics has incurred significant losses since inception and faces substantial doubt about its ability to continue as a going concern without additional capital. Revenue declined 7% in 2025, driven by decreases in service revenue and instrument sales. The company faces ongoing risks from geopolitical tensions, supply chain disruptions, and funding headwinds in key regions such as Asia Pacific. The shift in business strategy to focus on utilization of existing instruments may limit new revenue growth from instrument placements. Liquidity remains constrained with limited cash reserves and a need for capital raises. Failure to secure additional financing or execute strategic alternatives could impair operations and investor value.

Bionano Genomics' moat is based on its proprietary optical genome mapping technology and integrated software solutions that provide comprehensive genomic analysis by combining OGM with next-generation sequencing and microarray data. Its reagent rental program creates recurring consumable revenue tied to installed instruments, fostering customer lock-in. The company's specialized nucleic acid extraction technology and diagnostic testing services further differentiate its offerings. However, the market is competitive with alternative genomic technologies, and the company faces challenges in scaling adoption and managing supply chain dependencies. Its intellectual property, integrated platform, and established installed base contribute to its competitive positioning.

• Liquidity and Going Concern Risk: The company has recurring operating losses and substantial doubt about its ability to continue as a going concern within 12 months without additional capital. Failure to raise sufficient funds may lead to reorganization or liquidation.
• Geopolitical and Macroeconomic Risks: Adverse geopolitical events, including conflicts and sanctions, and macroeconomic conditions such as inflation and supply chain disruptions could materially impact operations and financial results.
• Supply Chain Dependencies: Bionano relies on single or limited sources for materials and contract manufacturing. Disruptions or cost increases in supply chain could affect product availability and margins.
• Market Adoption and Competition: The company’s technology competes with alternative genomic analysis methods. Adoption rates and competitive pressures may affect revenue growth and market share.
• Regional Funding Headwinds: Slowdown in Asia Pacific business due to government funding challenges impacts manufacturing partners and sales in that region.

• Bionano Genomics, Inc. provides genome analysis solutions including optical genome mapping (OGM) systems, diagnostic services, and software.
• The company offers OGM solutions for basic, translational, and clinical research, as well as bioprocessing applications.
• It provides a platform-agnostic software solution integrating next-generation sequencing, microarray, and OGM data for comprehensive genomic analysis.
• Bionano also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology.
• Through Bionano Laboratories, the company provides OGM-based diagnostic testing services.
• The installed base of OGM instruments grew to 387 units as of December 31, 2025, a 4.3% increase from 371 units at the end of 2024.
• In 2025, the company sold 30,171 flowcells, a slight decrease of 0.4% compared to 2024.
• Revenue for the year ended December 31, 2025 was $28.5 million, a 7% decrease from $30.8 million in 2024, primarily due to a decline in service and other revenue.
• Product revenue was $26.7 million in 2025, nearly flat compared to 2024.
• Geographically, revenue was distributed as 42.7% Americas, 49.5% EMEA, and 7.8% Asia Pacific in 2025.
• Net loss for 2025 was $26.4 million, a significant improvement from a $112.0 million loss in 2024.
• Basic and diluted net loss per share was $4.85 for 2025.
• The company had $3.0 million in cash and cash equivalents as of December 31, 2025, with a current ratio of 1.98 and a cash ratio of 0.13.
• Bionano operates under a reagent rental program providing instruments at no cost in exchange for minimum consumable purchases.
• The company has experienced supply chain challenges and geopolitical risks, including impacts from international conflicts and government funding slowdowns in Asia Pacific.
• Bionano has restructured its business strategy to focus on driving utilization and adoption of OGM from its existing installed base rather than new instrument placements.
• The company has incurred losses since inception and has substantial doubt about its ability to continue as a going concern without additional capital.
• Bionano has a shelf registration statement for up to $400 million in securities and an ATM agreement for up to $75 million to raise capital.
• The company expects to continue incurring significant expenses in sales, marketing, research and development, and public company costs.
• Bionano's customers include academic and governmental research institutions, clinical laboratories, pharmaceutical, biotechnology, and contract research companies.
• The company sells its VIA software on a subscription basis, which integrates OGM data with NGS and microarray workflows.
• Cost of product revenue decreased significantly in 2025 due to prior year inventory write-offs and restructuring.
• The company discontinued certain clinical service offerings in 2024, impacting service revenue.
• Bionano's revenue by geography shows a decline in Asia Pacific due to funding headwinds affecting manufacturing partners.
• The company is monitoring the impact of the U.S. government shutdown and geopolitical risks on its operations and supply chain.
• Bionano's board maintains a strategy committee to evaluate alternatives including financing, combinations, or sale of the company.
• Recent news includes earnings call transcripts and analyst coverage maintaining buy recommendations [N1][N3][N4].